Skip to content

Acurx Pharmaceuticals, Inc.

ACXP

CIK 0001736243

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$8.07M
+43.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$5.89
+69.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$14.46M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
4.3M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Recent filings